Cabinet for Economic Development
Governor Beshear Announces Louisville Life Science Company to Produce Equine Drug

Press Release Date:  Monday, November 29, 2010  
Contact Information:  Mandy Lambert, (502) 564-7670  


First of its kind developed and manufactured in Kentucky

LOUISVILLE, Ky. (Nov. 29, 2010) – Gov. Steve Beshear today announced that CreoSalus, a Louisville life science company, has obtained Federal Drug Administration approval for its subsidiary, Thorn BioScience, to produce and market an equine drug. SucroMate™ Equine is only the eighth new animal health drug approved by the FDA this year and the first of its kind to be developed and manufactured in Kentucky. 

CreoSalus was awarded $750,000 in 2007 from the Cabinet for Economic Development, through its Department of Commercialization and Innovation, to support the development of SucroMateTM Equine, which regulates ovulation in mares to increase the likelihood of conception when breeding horses. 

“This new drug will have a tremendous positive impact on horse breeding in Kentucky and across the world,” said Gov. Beshear. “I’m proud that Kentuckians have developed this breakthrough product and will manufacture it here in the horse capital of the world The engineering and technical jobs created to date and those expected in the future are the types of high-tech jobs that help Kentucky retain its highly skilled workers.”    

As part of obtaining FDA approval for SucroMate™ Equine, CreoSalus built the Commonwealth’s only Class 100 sterile injectable filling room for pharmaceutical production. In the next year, CreoSalus will also begin soliciting production work for drugs currently being produced in other states.   

“The development and manufacture of SucroMate™ Equine in Kentucky is a testament to how far Kentucky has progressed as a leader in the healthcare and high-tech industries,” said Jim Geisler, COO and CFO of CreoSalus. “CreoSalus, Latin for “create good health,” is part of Louisville’s growing life science industry.”  

The development of SucroMate™ Equine was launched twelve years ago at Thorn BioScience, which produces finished drugs as part of CreoSalus. The two other divisions within CreoSalus include Advanced ChemTech, which produces fine chemicals, and Occam Design, which makes human medical devices. All are based in Louisville. 

“CreoSalus CEO David Phelps and his team have worked for many years to achieve this major accomplishment,” said Louisville Mayor Jerry Abramson. “We believed in their vision and they believed in Louisville.” 

“SucroMate™ Equine is the first of a series of animal ovulation drugs under development by CreoSalus,” added Phelps. “Work is well underway on similar drugs for pigs and cows that could transform breeding operations for beef and pork producers and result in additional, high-quality job growth at CreoSalus.” 

CreoSalus has signed a national distribution agreement for SucroMate™ Equine with Bioniche Life Sciences, a Canadian public company. “SucroMate™ Equine is a natural fit with our portfolio of reproductive drugs for large animals, including horses,” said Jim Phillips, president of Bioniche’s Animal Health division. “With up to 300,000 mares bred annually, we believe the market prospects for this new product are strong.” 

Additional information on Kentucky’s economic development efforts and programs is available at www.ThinkKentucky.com. 

###